Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata
The suit was filed the same day Natera received a new patent covering its patient-specific residual cancer testing and monitoring methods.
Company leaders said that practical steps are being taken to recover from earlier underperformance and support planned growth in NGS and residual disease testing.
The firm has submitted data to the Centers for Medicare and Medicaid Services' MolDx program to pursue reimbursement.
Princess Margaret Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
Inivata's InVisionFirst-Lung and RaDaR assays will support studies of the use of liquid biopsies in early and minimal residual disease detection.
Agendia to Distribute Inivata Liquid Biopsy Breast Cancer Test in North America, Europe
Agendia will receive co-exclusive rights to distribute Inivata's RaDaR assay for minimal residual disease and relapse detection in Europe and North America.